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Background: In the evolving field of transcatheter aortic valve replacements a new generation of valves have been
introduced to clinical practice. With the complexity of the TAVR procedure and the unique aspects of each TAVR
device, there is a perceived risk that changing or adding a new valve in a department could lead to a worse outcome
for patients, especially during the learning phase. The objective was to study the safety aspect of introducing a second
generation repositionable transcatheter valve (Boston Scientific Lotus valve besides Edwards Sapien valve) in a
department.
Methods: In a retrospective study, 53 patients receiving the Lotus system, and 47 patients receiving the Sapien system
over a period of three years were compared for short-term outcome according to VARC-2 definitions and 1-year survival.
Results: Outcome in terms VARC-2 criteria for early safety and clinical efficacy, stroke rate, and survival at 30 days and at
1 year were similar. The Lotus valve had less paravalvular leakage, where 90% had none or trace aortic insufficiency as
compared to only 48% for the Sapien system.
Conclusions: Introduction of a new generation valve can be done with early device success and safety, and without
jeopardizing the outcome for patients up to one year. We found no adverse effects by changing valve type and
observed improved outcome in terms of lower PVL-rates. Both existing and new centers starting a TAVR program can
benefit from the use of a new generation device.Background
Transcatheter Aortic Valve Replacements (TAVR) has
grown rapidly in the last years, and the outcome in terms
of survival is good for a high-risk group of patients [1, 2].
Presently, the self-expanding and balloon expandable sys-
tems have dominated, and large randomized clinical stud-
ies have established their safety and efficacy [1, 3]. Despite
good clinical outcomes these valves exhibit some inherent
technical limitations. Specifically paravalvular leak (PVL)
and malposition of the valve are two problems that have* Correspondence: henrik.bjursten@med.lu.se
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have been designed to address some of these issues, and
recently Boston Scientific introduced a second-generation
TAVR device which addressed both PVL and malposition,
as it has an adaptive seal and is also fully repositionable
and retrievable [7, 8].
With increasing number of interventions and new de-
vices on the market, many centers will need to decide if
they should change to a new device, use several devices in
their practice or keep using the single device they have lar-
gest experience with. Given the complexity of the proce-
dures and the frailty of the patients being treated, this
decision to change is not always easy. Using an established
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the other hand introducing a second device with different
characteristics could increase the ability to individualize
therapy for the patient in order to improve outcome.
The Boston Scientific Lotus system was introduced in
2013 in our department. This provided us with an oppor-
tunity to study the safety of introducing a new valve in
terms of both short-term safety and survival. To our
knowledge, there are no randomized studies comparing a
TAVR-valve against another, and therefore a retrospective
study will provide us with indicative information on per-
formance. The aim of this retrospective study was thus to
compare the outcome of the two valves during a well-
defined time period in terms of device success, early safety
as defined by VARC-2, and 1-year survival.
Methods
Study design
Our TAVR-program started in 2007, and since its incep-
tion we have used the available balloon-expandable
Sapien™ valve system (THV, XT, S3, Edwards Lifescience,
Irvine, CA, USA). In 2013 we participated in the REPRISE
II study [7, 9] and the repositionable Boston Lotus™ valve
system (Boston Scientific, Marlborough, MA) was intro-
duced in the department. After gaining initial clinical ex-
perience we decided to use the Boston Lotus as the
primary valve when anatomically feasible. This retrospect-
ive study includes all transfemoral TAVR performed from
1st of January 2012 to 31st of December 2014 at Skane
University Hospital, Lund, Sweden. The study was ap-
proved by the local ethics committee (LU 2009/87).
Patient selection
Patients included all had a severe symptomatic aortic
stenosis. They were selected for TAVR either because
they were denied conventional surgery, were frail, old
age (>85 years) or other clinical reasons that they would
benefit from a TAVR by a multidisciplinary team consist-
ing of at least one cardiologist and cardiac surgeon. By
performing a TAVR, the patients were expected to have
a survival of at least one year, and an increase in quality
of life. Only patients suited for a transfemoral access
were included in this study, and the other patients were
treated with an alternative access by the same team that
performed the transfemoral cases.
Implantation technique
All procedures were performed in a dedicated hybrid oper-
ation room with at least one interventional cardiologist
and one cardiac surgeon performing the procedure to-
gether. In the beginning of the study period, all patients
underwent general anesthesia, and during the study period
conscious sedation was introduced. For both devices, fem-
oral access was obtained by cut-down or by percutaneouspuncture with subsequent closing of the puncture site with
a closure device. Heparin was given to achieve an ACT-
level > 250 s. Pre-dilatation was performed in the majority
of cases, unless the pre-operative CT had a low calcium
burden in the native valve. Ventricular rapid pacing was
used for all Edwards Sapien valve implantations, and for
the balloon valvuloplasty in about one third of the Lotus
implantations. The implantation technique for Edwards
Sapien and Boston Lotus system have been described in
detail elsewhere [1, 7]. Sizing of the valve was performed
according to the manufacturers’ recommendations.
Data sources
Peri-operative data for the study was retrieved from three
principal sources. Base-line characteristics and intra-
procedural data was obtained from SWEDEHEART,
which is a national quality registry including all invasive
cardiac procedures in Sweden. This registry also contains
survival data for patients. In the case of missing data, add-
itional data were retrieved from the electronic medical re-
cords. Early safety according to VARC-2-criteria was
registered by retrospectively reviewing the electronic med-
ical records for the patients [10]. Pre- and post-operative
echocardiographical examinations were re-assessed by an
independent, blinded, and experienced echocardiographer
(MD). Post-operative echocardiography was performed
the days after implantation.
Statistics
Continuous data were presented as mean ± one standard
deviation and proportions as percent and number. A
two-tailed t-test was performed for comparison of con-
tinuous variables, and a two-tailed Fishers exact test for
dichotomous variables. The Kaplan-Meier estimate was
used to illustrate survival after valve implantation. Cal-
culations and graphs were made with Statistica version
version 12 (Statsoft, Tulsa, OK) and Stata version 14
(Statacorp, Collage station, TX).
Results
A total of 100 patients were included in this study,
where 47 received the Edwards Sapien valve (40 Sapien
XT and 7 Sapien-3), and 53 received the Boston Lotus
valve. Size distribution between the valves were similar,
but Sapien spanned over a wider range (Table 1). One
patient had a device failure with the Lotus system, and
returned 42 days later for a successful new Lotus im-
plantation from the contralateral side. Thus, there were
54 Boston Lotus implantations during the study
period (implantations are presented with n = 54 and
patients n = 53 for the Lotus in this report). There
were more Sapien implants in the beginning of the
study period, and more Lotus implants in the end of
the study period (Fig. 1).
Table 1 Distribution of valves
Size (mm) Lotus Sapien-3 Sapien-XT
20 1





Total 53 7 40
Distribution of valves by type/manufacturer and valve sizes
Table 2 Patient characteristics
Lotus (n = 53) Sapien (n = 47) p-value
Age (years) 84.1 (4.9) 77.1 (11.5) 0.0001
Male 35.8% (19) 53.2% (25) 0.1068
Diabetes mellitus 15.1% (8) 25.5% (12) 0.2186
COPD 7.5% (4) 17% (8) 0.2179
Hypertension 77.4% (41) 80.9% (38) 0.8067
Recent myocardial infarction 15.1% (8) 6.4% (3) 0.2096
Previous stroke 17% (9) 25.5% (12) 0.3327
Peripheral vascular disease 15.1% (8) 14.9% (7) 1.0000
Atrial fibrillation 43.4% (23) 25.5% (12) 0.0923
Pre-op dialysis 0% (0) 2.1% (1) 0.4700
Previous cardiac surgery 22.6% (12) 19.1% (9) 0.8067
Previous PCI 20.8% (11) 27.7% (13) 0.4855
NYHA I 0% (0) 0% (0)
NYHA II 5.7% (3) 14.9% (7) 0.1831
NYHA III 71.7% (38) 76.6% (36) 0.6513
NYHA IV 22.6% (12) 8.5% (4) 0.0619
Denied surgical AVR 60.4% (32) 76.6% (36) 0.0912
Pre-op creatinine mmol/L 101.1 (42.2) 109.2 (63.6) 0.4542
EuroSCORE I 25.3 (12.3) 18,2 (10.7) 0.0030
EuroSCORE II 7.8 (4.6) 5.8 (4.8) 0.0378
STS score 7.1 (4.4) 6.3 (7.5) 0.4880
Valve-in-Valve 0% (0) 6.4% (3) 0.1003
Patient characteristics for the patients in the study
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Lotus group were older (84.1 ± 4.9 vs 77.1 ± 11.5 years,
p < 0.001), had higher EuroScore I (25.3 ± 12.3 vs 18.2 ±
10.8, p < 0.005) and EuroScore II (7.8 ± 4.6 vs. 5.8 ± 4.8,
p < 0.05, Table 2). The Lotus group had higher pre-
operative peak gradient (80.0 ± 17.9 vs 71.7 ± 18.8 mmHg,
p < 0.05).
For procedural data, the Lotus group had a shorter pro-
cedure time (82.9 ± 31.0 vs 118.7 ± 99.7 min, p < 0.05),
lower frequency of rapid pacing (22% vs 100%, p < 0.0001),
lower frequency of general anesthesia (39% vs 100%,
p < 0.0001), less periprocedural bleeding (105 ± 160 vs
203 ± 287 ml, p < 0.05, Table 3). Early safety according
to the VARC-2-criteria was similar between the groups
(Table 4). The Lotus group had a trend towards a higher
stroke rate (9% vs 0%, p = 0.0585). Of the 5 patients that
had a periprocedural stroke, two were major and three










Fig. 1 Distribution between Edwards Sapien valve (blue solid), Boston Lotus valve (Green shaded) and alternate access during the study period
(red striped) during the study period for transfemoral approach






Procedural time (min) 82.9 (31.0) 118.7 (99.7) 0.0169
Fluoroscopy time (min) 29.7 (12.3) 26.2 (13.3) 0.1637
Contrast (mL) 92.6 (31.0) 99.3 (32.1) 0.2856
General anesthesia 39.0% (21) 100% (47) 0.0000
Pre-dilatation 59.3% (32) 83% (39) 0.0089
Post-dilatation 0% (0) 27.7% (13) 0.0000
Rapid Pacing 22.2% (12) 100% (47) 0.0000
Per-op bleeding (mL) 105.1 (159.9) 202.8 (287.4) 0.0355
Heart-lung machine (unplanned) 1.9% (1) 8.5% (4) 0.1927
New pacemaker 15.1% (8) 6.8% (3) 0.2172
Aortic valve malpositioning 0% (0) 0% (0)
Valve migration 0% (0) 0% (0)
Valve embolization 0% (0) 0% (0)
Ectopic valve deployment 0% (0) 0% (0)
TAV-in-TAV deployment 0% (0) 0% (0)
Procedural data in all 54 Lotus procedures, but new pacemaker reported for
the 53 patients
Table 4 Device Success, Outcome and Safety according to
VARC-2
Lotus (n = 53) Sapien (n = 47) p-value
Device Success (n = 54
for Lotus)a
98.1% (53) 91.5% (43) 0.1809
Absence of procedural
mortality
100% (54) 97.9% (46) 0.4653
Correct positioning of
single valve in correct
anatomical position
98.1% (53) 97.9% (46) 1.0000
Intended performance
of prosthetic heart valve
100% (54) 95.7% (45) 0.2141
Early safety at 30 days 96.2% (51) 89.4% (42) 0.2486
All-cause mortality 3.8% (2) 10.6% (5) 0.2486
All stroke 9.4% (5) 0% (0) 0.0585
Life-threatening
bleeding
1.9% (1) 10.6% (5) 0.0965
Acute kidney injury
stage I
1.9% (1) 14.9% (7) 0.0244
Acute kidney injury
stage II
1.9% (1) 0% (0) 1.0000
Coronary artery obstruction
requiring intervention
0% (0) 2.1% (1) 0.4700
Major vascular complication 1.9% (1) 6.4% (3) 0.4968
Valve-related dysfunction
requiring repeat procedure
0% (0) 0% (0)
Clinical efficacy at 30 days
Mortality 3.8% (2) 10.6% (5) 0.2486
All stroke 9.4% (5) 0% (0) 0.0585
Major stroke 3.8% (2) 0% (0) 0.4968
Rehospitalization for
valve-related symptoms
1.9% (1) 6.4% (3) 0.3393
Valve endocarditis 0% (0) 0% (0)
Valve related dysfunction 0% (0) 4.3% (2) 0.2184
Device Success, Outcome and Safety according to VARC-2. aFor Device success
all implantations For Lotus (n = 54) are reported, but for 30-day outcome all
patients are reported (n = 53)
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98% (all but one patient) for the Lotus group and 91% (all
but 4 patients) for the Sapien group (p = 0.1809, Table 4).
In the Lotus group, in one patient the device malfunc-
tioned when a reposition was performed, and had to be
recaptured and removed. The patient had to undergo a re-
construction of the femoral artery as a consequence and
received another Lotus valve 42 days later. In the Sapien
group, one patient suffered an aortic annular rupture and
was converted to open heart surgery but could not be
saved, and one patient required a second valve due too
low placement resulting in aortic regurgitation. Two
patients in the Sapien group did not met VARC-2-criteria
for valve performance.
The re-assessed and blinded post-operative echocardi-
ography showed that the Lotus valve had less paravalvu-
lar leakage, 58% had no PVL compared to 26% for
Sapien (p < 0.005). In the Lotus group 10% had a mild
PVL compared to 48% in the Sapien group (p < 0.0005).
There were no patients with mild-moderate or moderate
PVL in the Lotus group compared to 10% in the Sapien
group (Table 5).
The thirty day mortality was 3.8% (2 patients) in
the Lotus group and 10.6% (5 patients) in the Sapien
group (p = 0.2486, Table 4). One year mortality was
7.5% (4 patients) in the Lotus group and 17.0% (7 patients)
in the Sapien group (p = 0.3397, Fig. 2).
Discussion
The aim of this study was to evaluate whether changing
from a first-generation valve to a second-generation valvecould be performed safely without affecting outcome for
the patients. The study can conclude that safety and effi-
cacy are maintained up to one year.
Despite the differences in the demographics between
the groups, it is interesting to compare outcome in terms
of prosthesis function, as it determines treatment effect
and outcome. Paravalvular leakage is still the Achilles heel
of TAVR, and several studies have demonstrated the nega-
tive impact of short and long-term mortality from PVL
[11–13]. We found a large difference in paravalvular leak-
age. For the Lotus valve, 90% had none or trace PVL,
whereas for the Sapien 48% had none or trace PVL by
blinded echo evaluation. There were no mild-moderate or
above PVL for the Lotus, whereas the Sapien had 5%
mild-moderate PVL. It should be noted that the majority
of Sapien cases were performed with Sapien XT, and the
Table 5 Pre-and post-operative echo
Pre-operative Lotus (n = 53) Sapien (n = 47) p-value
Ejection Fraction
EF > 50% 67.9% (36) 55.3% (26) 0.2203
EF 30-50% 26.4% (14) 29.8% (14) 0.8241
EF < 30% 5.7% (3) 14.9% (7) 0.1831
Mitral regurgitation
None 5.7% (3) 4.3% (2) 1.0000
Trace 34% (18) 23.4% (11) 0.3797
Mild 43.4% (23) 48.9% (23) 0.6882
Mild-Moderate 7.5% (4) 17% (8) 0.2179
Moderate 7.5% (4) 6.4% (3) 1.0000
Aortic stenosis
Peak velocity 4.5 (0.5) 4.2 (0.6) 0.0141
Peak gradient 80 (17.9) 71.7 (18.8) 0.0275
Aortic valve area (cm2) 0.6 (0.2) 0.6 (0.2) 0.0860
Post-operative Lotus (n = 50) Sapien (n = 42) p-value
Ejection fraction
EF > 50% 74% (37) 64.3% (27) 0.2171
EF 30-50% 24% (12) 26.2% (11) 1.0000
EF < 30% 2% (1) 9.5% (4) 0.1841
Aortic regurgitation
None 58% (29) 26.2% (11) 0.0020
Trace 32% (16) 21.4% (9) 0.2505
Mild 10% (5) 47.6% (20) 0.0002
Mild-moderate 0% (0) 4.8% (2) 0.2184
Moderate 0% (0) 0% (0)
Mitral regurgitation
None 4% (2) 0% (0) 0.4982
Trace 36% (18) 47.6% (20) 0.4114
Mild 46% (23) 42.9% (18) 0.4881
Mild-Moderate 0% (0) 4.8% (2) 0.1669
Moderate 14% (7) 4.8% (2) 0.1669
Aortic stenosis
Peak velocity 2.1 (0.4) 2 (0.5) 0.0838
Peak gradient 18.9 (6.9) 16.5 (8.3) 0.1405
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Fig. 2 Kaplan-Meier estimated of 1-year survival for Boston Lotus
vale (solid blue line) and Edwards Sapien valve (broken red line)
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of PVL [14, 15]. These figures can still be benchmarked
against the incidence of moderate or above PVL in larger
studies, where the Lotus valve system had a 1% frequency,
the Sapien 3 had a 3,3% frequency, and the Sapien XT had
a 13% frequency [7, 14] of moderate to severe PVL. How-
ever, the Sapien-3 is not retrievable or repositionable, and
PVL can only be addressed with post-dilation. This will
likely result in a higher degree of PVL for Sapien-3compared to Lotus in larger series. The results of 90%
with none or trace PVL for the Lotus system is in range,
and even better than, the REPRISE II study where 80%
came in this category [9]. There were no measurable dif-
ferences in peak gradient over the valve after implantation
between the groups.
Although not statistically significant, the permanent
pacemaker rate was numerically higher in the Lotus group
as compared to the Sapien group. The Sapien group had
7% pacemaker rate, which is in line with a recent large
meta-analysis were the median pacemaker rate was 6%
[16]. The Lotus group had a 15% pacemaker rate, which is
lower than the 36% reported in the REPRISE I Study and
the 29% reported in the REPRISE II study [7, 8]. The best
explanation for this is probably that we have adopted a
new deployment method for the valve, where we keep the
valve in a high position during the entire deployment;
never allowing Lotus to drop down into the outflow tract
of the ventricle as compared to the traditional way of
deploying the valve where retraction is performed in the
outflow tract that potentially can scrape the septum and
damage the conduction system. Another explanation is a
careful pre-operative assessment with gated computer
tomography in order to avoid oversizing of the valve. His-
torically, the high pacemaker rate has been one of the
drawbacks with the Lotus valve, but maybe an improved
deployment technique as outlined above can address this.
There were no statistical differences in either 30-day or
1-year mortality between the groups, despite Lotus-
patients being older with more co-morbidities, had higher
pre-gradient and higher EuroScore I and II. This may be
attributed to several other factors such as patient selec-
tion. It still shows that the Lotus Valve can safely be
adopted in a TAVR centre with equally good, and poten-
tially better, outcome. The safety aspect of a second gener-
ation valve will be pivotal once intermediate risk patient
Bjursten et al. BMC Cardiovascular Disorders  (2017) 17:25 Page 6 of 7are considered for a TAVR, as surgery not only places the
correct valve in the correct position with minimal PVL,
but also has a high predictable safety of the procedure. It
will therefore not suffice to only address malpositioning
and PVL with a second-generation valve, but safety should
never be jeopardized.
There was trend towards a higher stroke rate with the
Lotus valve. Two patients experienced a major stroke
which was also the cause of death in the Lotus cohort,
whereas three had a minor stroke with good recovery. The
Lotus system has a larger diameter (18 F and 20 F ID), this
may account for this observation, but interestingly French
size did not reflect in higher bleeding or vascular
complications. The system is more rigid which also could
be a reason for the increased stroke rate. We believe this
should warrant for care in porcelains aortas or aortas with
severe tortuosity, particularly in the learning phase.
The main limitations of this analysis are the relatively
small sample size and the lack of randomization between
the groups. As the Lotus group was performed later in
time, they could benefit from improvements in periopera-
tive care, such as conscious sedation and more frequent
use of closure devices and more experienced operators.
Moreover there is a selection bias, as patients not suited
for a Lotus valve in the later period received a Sapien
valve. The reason for this was poor access, too large or
too small annulus. On the other hand we preferred the
Lotus valve in patients with small sinuses of Valsalva or
short distance to the coronaries as it is repositionable.
Another aspect is that we have not taken into account the
learning curve for the new valve in this study, potentially
distorting results in favor of the older valve. Still we be-
lieve that the material can be used to test the hypothesis
that changing to a new generation valve does not harm
the patients, despite the learning curve associated with a
new device. One strength of the study is that we had all
echocardiographic examinations re-assessed by a
blinded, independent and experienced echocardiog-
rapher, which underlines our findings regarding the re-
duced PVL in the Lotus group. In the absence of
randomized studies, we believe that this study can be
used both for generating hypothesis for future studies,
and decisions which valve to use.
Conclusions
Despite the inherent difficulties in performing a non-
randomized retrospective study with subsequent differ-
ences between the groups makes it treacherous to draw
any far-reaching conclusions. Still, as there were a lower
rate of PVL together with a trend towards improved out-
come according to VARC-2 criteria and lower 30-day and
1-year mortality, it is reasonable to conclude that patients
are not harmed by introduction of repositionable valve in
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